Major Depressive Disorder Pipeline Analysis Report 2026

Report Coverage

The Major Depressive Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into major depressive disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for major depressive disorder. The major depressive disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The major depressive disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with major depressive disorder treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to major depressive disorder.

Read more about this report - Request a Free Sample

Major Depressive Disorder Pipeline Outlook

The major depressive disorder pipeline is gaining momentum as developers pursue treatments for patients who respond poorly to standard antidepressants. In November 2025, the FDA approved Caplyta (lumateperone) as an adjunctive therapy for adults with MDD, following the January 17, 2025 approval of Spravato as monotherapy for treatment-resistant depression. These approvals highlight growing interest in faster-acting options, new mechanisms, improved tolerability, and more personalized treatment approaches for patients with persistent depressive symptoms across diverse adult patient populations in practice.

Major Depressive Disorder Epidemiology

Major depressive disorder remains a substantial public health burden worldwide. The World Health Organization estimates that depression affected about 332 million people globally in 2021, with women affected more often than men. In the United States, CDC data covering August 2021 to August 2023 found depression in 13.1% of people aged 12 years and older. Rates were higher among younger people, females, and lower-income groups, and 87.9% of affected individuals reported difficulty with work, home, or social activities during their normal daily lives.

Major Depressive Disorder – Pipeline Therapeutic Assessment

Major Depressive Disorder Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total major depressive disorder clinical trials. Early phase I (3.96%), phase I (15.35%), phase II (41.58%), phase III (21.78%) and phase IV (17.33%). The report provides comprehensive insights into the distribution of drug candidates across different stages of clinical development, highlighting the evolving landscape and advancement of the major depressive disorder pipeline.

Major Depressive Disorder Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the major depressive disorder pipeline analysis include small molecules, monoclonal antibodies, and peptides. The major depressive disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for major depressive disorder. In January 2025, the FDA expanded the indication for Spravato (esketamine) nasal spray, allowing it to be used without an oral antidepressant in adults with treatment-resistant depression, a form of MDD involving an inadequate response to at least two oral antidepressants, thereby broadening treatment options for patients with difficult-to-treat depression.

Major Depressive Disorder Clinical Trials – Key Players

The EMR report for the major depressive disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed major depressive disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in major depressive disorder clinical trials:

• Corium Innovations, Inc.
• Mitacs
• iMediSync
• Axsome Therapeutics, Inc.
• Alto Neuroscience, Inc.
• Neumora Therapeutics
• Relmada Therapeutics, Inc.
• Compass Pathways plc
• Sage Therapeutics, Inc.
• Neurocrine Biosciences, Inc.
• Xenon Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co., Ltd.

Major Depressive Disorder – Emerging Drugs Profile

Key Questions Answered in the Major Depressive Disorder Pipeline Insight Report

• Which companies/institutions are leading the major depressive disorder drug development?
• Which company is leading the major depressive disorder pipeline development activities?
• What is the current major depressive disorder commercial assessment?
• What are the opportunities and challenges present in the major depressive disorder pipeline landscape?
• What is the efficacy and safety profile of major depressive disorder pipeline drugs?
• Which company is conducting major trials for major depressive disorder drugs?
• Which companies/institutions are involved in major depressive disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in major depressive disorder?

Reasons To Buy This Report

The Major Depressive Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for major depressive disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into major depressive disorder collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Anxiety and Depression Treatment Market

Treatment Resistant Depression Market

Treatment Resistant Depression Pipeline Analysis Report